Inventiva S.A. (0RNK.L)
| Chiusura precedente | 6,52 |
| Aperto | 6,68 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 6,68 - 6,74 |
| Intervallo di 52 settimane | 6,68 - 6,74 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 127,566M |
| Beta (5 anni mensile) | 1,00 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,27 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape by Dr. Stephen HarrisonPresentation by Dr. Michael Cooreman of three scientific abstracts from NATIVE selected for poster presentations at the EASL International Liver Congress™ 2022 Update on LEGEND, Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflozin in pati
- GlobeNewswire
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the reduction of the FastTM score in association with the beneficial effects of lanifibranor on liver histology and biologically relevant biomarkers, in patients with NASH and F2/F3 fibrosis.the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibran
- GlobeNewswire
Inventiva joins the Euronext Tech Leaders segment
Inventiva has been selected for inclusion in Euronext’s new segment alongside more than 100 high-growth and Tech-driven European companiesInternational investors will be able to track the Euronext Tech Leaders segment through a new index Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of pati
